Tonghua Dongbao Pharmaceutical Co., Ltd
6 articles about Tonghua Dongbao Pharmaceutical Co., Ltd
-
Meitheal Announces Exclusive Commercial Licensing Agreement for Insulin Biosimilars in the U.S.
9/21/2023
Meitheal Pharmaceuticals, Inc. announced an exclusive licensing agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. (THDB) to commercialize three insulin biosimilars — insulin aspart, insulin lispro, and insulin glargine — in the U.S.
-
Adocia’s Partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China
10/14/2021
Adocia announced that its partner Tonghua Dongbao Pharmaceutical Co. Ltd. received clearance from the Center for Drug Evaluation of the China National Medical Products Administration to conduct the Phase 3 clinical trial of BioChaperone® Lispro, an Ultra-Rapid Insulin for the treatment of Type 1 and Type 2 diabetes.
-
Shares of Adocia are up nearly 30 percent this morning after the company announced it granted exclusive development and commercialization rights of its insulin products to Tonghua Dongbao Pharmaceuticals.
-
Dance Biopharm's China Licensee, Harmony Biopharm, Enters Into New Joint Venture With Tonghua Dongbao Pharmaceutical Co., Ltd, A Leading China Insulin Producer
5/6/2016
-
Tonghua Dongbao Pharmaceutical Co., Ltd To Build $59 Million Insulin Manufacturing Facility
4/10/2015
-
Lijun International Pharma and Tonghua Dongbao Pharmaceutical Co., Ltd Set Up IV Joint Venture
7/23/2010